HIV Drug Buyers Want Gilead Product Switch Claims Revived <https://www.law360.com/competition/articles/2259662?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-11-13&read_main=1&nlsidx=0&nlaidx=9> By Bryan Koenig Insurers and benefit plans are asking the Ninth Circuit to revive a chunk of their antitrust case against Gilead, arguing their claims that Gilead delayed generic competition to its HIV drugs by monopolizing the market should have new life. Brief attached | Read full article » <https://www.law360.com/competition/articles/2259662?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-11-13&read_more=1&nlsidx=0&nlaidx=9> | Save to favorites » <https://www.law360.com/competition/articles/2259662?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-11-13&read_later=1&nlsidx=0&nlaidx=9>